Do you need to get your patient with myeloma into CR prior to autologous transplant?
Answers to this and many other key questions in newly diagnosed myeloma with the eloquent and wise @VincentRK on @BloodCancerTalk - wherever you get your podcasts
#mmsm#myeloma@rajshekharucms
🎙️ New @BloodCancerTalks episode is live!
We sat down with the legendary @VincentRK to discuss newly diagnosed #MultipleMyeloma — diagnosis, risk stratification, induction, when to transplant, and maintenance!
https://t.co/ViiO4qsr8d
Our 1st episode of 2026 just dropped! MajesTEC-3 and the Bispecific Revolution!
First author @LucianoCostaMD walks us through the nuts and bolts of the data and how BCMA BsAbs will disrupt the treatment paradigm at early relapse!
https://t.co/H73YPTX9lS
#ASH25#mmsm
Tune in to our new episode on International #Myeloma Society 2025 Updates with key abstracts ranging from smoldering myeloma to relapsed/refractory myeloma with @AlGarfall!
https://t.co/NtpYtVDUpB
🎙️ New episode alert! "ctDNA in DLBCL" now live on @BloodCancerTalk. Dive into the latest on circulating tumor DNA as a biomarker for diffuse large B-cell lymphoma monitoring and treatment decisions with experts @AshAlizadeh and @dgermain21!
https://t.co/tnZtK2SpAl
@Eddie_Cliff
Curious how ctDNA could reshape care for aggressive cancers like #DLBCL? Hear from co-founder Ash Alizadeh on its potential, from advances in detection to breakthrough clinical data. Listen here: https://t.co/i0s7snKOht @BloodCancerTalk@rajshekharucms@AshKishtagari@Eddie_Cliff
🎙️ New episode alert! "ctDNA in DLBCL" now live on @BloodCancerTalk. Dive into the latest on circulating tumor DNA as a biomarker for diffuse large B-cell lymphoma monitoring and treatment decisions with experts @AshAlizadeh and @dgermain21!
https://t.co/tnZtK2SpAl
@Eddie_Cliff
Tune in to our new episode on EHA and ICML 2025 updates in #lymphoma with @AdrianMinson@PeterMacCC!
https://t.co/sZdl0XYSBh
Here is a clip of Dr. Minson's take on the Epcor + R-ICE data
Tune in to our new episode on EHA and ICML 2025 updates in #lymphoma with @AdrianMinson@PeterMacCC!
https://t.co/sZdl0XYSBh
Here is a clip of Dr. Minson's take on the Epcor + R-ICE data
🎧 NEW EPISODE ALERT! 🎧
Dive deep into follicular lymphoma management with Dr. Gilles Salles @MSKCancerCenter! From watchful waiting to bispecifics & CAR-T - we cover it all.
🔬 Key trials: RELEVANCE, GALLIUM, InMIND & more
Listen now! 🎙️
@Eddie_Cliff
https://t.co/alv2GpEM52
🎧 NEW EPISODE ALERT! 🎧
Dive deep into follicular lymphoma management with Dr. Gilles Salles @MSKCancerCenter! From watchful waiting to bispecifics & CAR-T - we cover it all.
🔬 Key trials: RELEVANCE, GALLIUM, InMIND & more
Listen now! 🎙️
@Eddie_Cliff
https://t.co/alv2GpEM52
MIDAS under the Microscope: Check out our special episode unpacking MIDAS trial in newly diagnosed #MultipleMyeloma with @MeeraMohanMD!
https://t.co/i0ZRHjauci
Missed our @young_eha session on clinical trial appraisal? Check out my short interview with @VJHemOnc on the importance of postprogression care in overall survival assessment
Examples: SHINE, TRIANGLE, ZUMA-7 & TRANSFORM.
https://t.co/dPwteHsawE #EHA2025@EHA_Hematology#lymsm
Our new episode on overview of Menin Inhibitors in AML with @Doctor_E_Stein from @MSKCancerCenter just dropped! We had a great discussion on the landscape of menin inhibitors, along with some clinical pearls from Dr. Stein on management!
https://t.co/EfS5chvT46
@AshKishtagari
Shamelessly stealing the concept of emergency podcasts from @RestIsPolitics but don’t worry we aren’t talking politics - we talk AQUILA, STARGLO, FDA ODAC
Come into the weeds of clinical trials with us
Glofitamab-GemOx for R/R DLBCL
#starglo#lymsm#ODAC@csoncol@OncoAlert